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ABSTRACT
Background: Hepatitis C virus (HCV) is a hepatotropic and lymphotropic virus that causes he-
patic and extrahepatic disease. Emerging clinical data suggest that chronic HCV infection can 
lead to many direct and indirect effects on the lung. 
Objectives: This article discusses evidence on the relationship between HCV infection and pul-
monary fibrosis to increase knowledge on this topic among clinicians and scientists and high-
lights the need for further study. 
Methods: We searched the MEDLINE, ISI WEB OF KNOWLEDGE, OVID, ELSEVIER, and MDCONSULT 
databases and top respiratory journals, such as the American Journal of Respiratory and Criti-
cal Care, Chest, and Thorax for articles in English using the following keywords: hepatitis C, 
HCV infection, IPF, pulmonary fibrosis, and interstitial pneumonitis. We reviewed the refer-
ence lists of all identified studies.
Results: The evidence for a pathogenetic link between pulmonary fibrosis and HCV is: the high-
er frequency of HCV markers in IPF patients, an increase in lymphocyte and neutrophil num-
bers in bronchoalveolar lavage of chronic HCV infection patients, and the development of IPF 
in HCV-related chronic hepatitis that is treated with interferon. There is a discrepancy between 
studies on the frequency of HCV in IPF patients, which might be attributed to geographical 
differences of in the prevalence of HCV infection, selection bias in choosing the control group, 
and the HCV genome.
Conclusions: BAL studies in HCV infection are associated with increased counts of lymphocytes 
and neutrophils in BAL fluid. These studies show that HCV infection is associated with non-
specific pulmonary inflammatory reactions that are not compatible with IPF but that it can 
lead to pulmonary fibrosis. The other factor is interferon therapy. Interstitial pneumonia and 
sarcoidosis are well-documented complications of IFN therapy. More extensive cohort studies 
should be conducted to confirm an actual causal relationship between HCV infection and pul-
monary fibrosis. 
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Hepatitis C virus (HCV) is a hepatotropic and lymphotropic 
virus that can cause hepatic and extrahepatic disease. Mixed 
cryoglobulinemia  and  non-Hodgkin’s  lymphoma  are  the 
two most common extrahepatic conditions that are linked 
most closely to HCV. Dermatological, nephrological, neuro-
logical, endocrinological, cardiocirculatory, and pulmonary 
disorders have also been associated with HCV infection (1, 2). 
Therefore, chronic HCV infection is a systemic disease that 
has a wide range of clinical manifestations. 
Emerging clinical data suggest that chronic HCV infection 
can lead to many direct and indirect effects on the lung. The 
direct effects include initiation or exacerbation of preexist-
ing asthma (3, 4) and COPD (5, 6), interstitial pneumonitis, 
and pulmonary fibrosis. Indirect effects comprise cirrhosis 
of the liver (due to HCV) with complications (hepatopulmo-
nary syndrome (7), port pulmonary hypertension (8), mixed 
cryoglobulinemia (9-11), Sicca syndrome (12), non-Hodgkin’s 
B-cell  lymphomas  (13),  autoimmune  thyroid  disease  (14), 
and myositis (15). 72 Aliannejad R  et al. Hepatitis C and pulmonary fibrosis
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The pathogenetic link between pulmonary fibrosis and HCV 
has been evidenced by the higher frequency of HCV mark-
ers in IPF patients, an increase in lymphocyte and neutrophil 
numbers in bronchoalveolar lavage of HCV chronic infection 
patients, and the development of IPF in HCV-related chronic 
hepatitis that is treated with interferon. Three years after the 
discovery  of  hepatitis  C,  Japanese  investigators  measured 
HCV antibodies in patients with idiopathic pulmonary fibro-
sis (IPF) and observed a higher prevalence of serum antibod-
ies to HCV in patients with IPF (28.8%) than in age-matched 
control subjects (3.6%) (16). Ohta et al. examined the involve-
ment of HCV in the pathogenesis of idiopathic pulmonary 
fibrosis (IPF). They measured anti-HCV antibodies by ELISA in 
the sera of 66 IPF patients and observed a high anti-HCV lev-
els in IPF compared with 9464 age-matched controls. Also, 
12.2% of ELISA-positive patients were positive by RIBA test, and 
14.3% of those who were pathologically diagnosed with UIP 
were positive for HCV by RT-PCR (17). Irving et al. examined 
the involvement of hepatitis C virus (HCV) infection in the 
pathogenesis of IPF, as suggested by Japanese researchers. 
They assessed the sera of 62 IPF patients using two second-
generation anti-HCV ELISAs and found that only one sample 
was reactive, which was negative for HCV RNA by RT-PCR. 
Consequently, they concluded that HCV infection was no 
more prevalent in British patients with IPF than in the gen-
eral population (18). Subsequently, Meliconi et al. tested the 
same hypothesis in Italy. Antibodies to HCV were measured 
in  60  patients  with  IPF,  130  patients  with  non-interstitial 
lung disease, and 4614 blood donors by ELISA and RIBA, and 
HCV-RNA was assessed by PCR. The prevalence of HCV infec-
tion and viral replication increased in Italian IPF patients, 
but the levels of anti-HCV antibodies did not differ versus 
other lung diseases (19). Similarly, Ferri et al. monitored the 
presence of lung disease in 300 patients with chronic HCV 
infection and found that 8 patients showed signs of inter-
stitial lung involvement by high-resolution CT (HRCT). The 
patients had varying degrees of DLCO reduction, and the 
percentage of neutrophils in BALF increased in 4 patients. 
One patient died from a rapidly progressive respiratory dis-
order, 2 patients deteriorated gradually, and 5 patients re-
mained stable (12). A recent retrospective cohort study was 
performed in 6150 Japanese HCV-infected patients and 2050 
hepatitis B virus patients (as a control group). The mean ob-
servation period was 8.0 ± 5.9 years in the HCV group and 6.3 
± 5.5 years in the HBV group. The cumulative rates of IPF de-
velopment in the HCV group were 0.3% at Year 10 and 0.9% at 
Year 20. The prevalence of IPF was slightly higher in the HCV 
group compared with the HBV group, and the rate of IPF in 
HCV patients was significantly greater in patients aged ≥ 55 
years, patients who had a smoking index ≥ 20, and patients 
with cirrhosis (20). 
The discrepancy between these results has several explana-
tions. The first is geographical differences in the prevalence 
of HCV infection, which is high in Japan and Mediterranean 
countries and low in northern Europe. Also, people who vol-
unteer as blood donors are generally not at risk for hepatitis 
viruses; thus, they do not represent the most appropriate 
control  group  since  they  were  younger.  Further,  the  HCV 
genome should be considered with regard to this discrep-
ancy. Keishi Kubo et al. studied BALF cell counts in 13 Japa-
nese patients with active chronic hepatitis C and 13 healthy 
volunteers. There was no difference in total cell counts in 
lavage fluid between the groups, but lavage lymphocyte and 
eosinophil numbers were higher in patients with chronic 
hepatitis C (21).
Yamaguchi  et  al.  performed  a  prospective  nonrandom-
ized study on BAL fluid in Japanese patients with chronic 
hepatitis C before and after treatment with interferon al-
pha  and  healthy  controls.  Lymphocyte  counts  in  the  BAL 
fluid increased significantly in both groups before and after 
treatment  compared  with  controls.  Activated  T  cell  (HLA-
DR-positive) counts rose in the pretreatment group versus 
the controls but fell after treatment compared with the pre-
treatment count. These findings suggest that HCV infection 
is associated with increased counts of lymphocytes and neu-
trophils in BAL fluid and that treatment with IFN-alpha ap-
pears to alter lymphocyte surface markers (22). 
Idilman et al. conducted the same study in 18 Turkish pa-
tients with chronic hepatitis C and 14 healthy volunteers. 
One patient (5.6%) only had HCV RNA in the bronchoalveolar 
lavage. The total cell and neutrophil counts in the BAL fluid 
were significantly higher in patients with chronic hepatitis 
C compared with controls. No difference was observed in 
the percentage of lymphocytes, macrophages, eosinophils, 
or T cell subsets or B cell numbers in BAL fluid between the 
groups (23). These studies indicated disparities in the cel-
lular content of BAL fluid in HCV hepatitis, some of which 
generated different results in comparison with BAL fluid fea-
tures of IPF. BAL fluid of IPF patients contain an excess of neu-
trophils, and lymphocytosis and eosinophil content of more 
than 20% in BAL fluid are not hallmarks of UIP/IPF (24). These 
studies on BALF cellular content were performed in HCV pa-
tients without evidence of pulmonary involvement. These 
reports demonstrate that HCV infection can be associated 
with  nonspecific  pulmonary  inflammatory  reactions  that 
are not compatible with IPF but that it can lead to pulmo-
nary fibrosis.Additional evidence of interstitial involvement 
in chronic HCV infection has come from measurements of 
epithelial  permeability  by  TC  99m  -labeled  diethylene  tri 
amin  pentaacetic  acid  aerosol  scintigraphy.  HCV-positive 
patients without clinical pulmonary symptoms have signifi-
cantly increased epithelial permeability compared with con-
trols, suggesting early interstitial lung disease (25). 
Interferon therapy should also be considered with regard 
to the link between pulmonary fibrosis and HCV. IFN has 
been used successfully to treat chronic HCV infection, but 
it  can  cause  pulmonary  complications.  Interstitial  pneu-
monia and sarcoidosis are well-documented complications 
of IFN therapy (26-28). The exact mechanism of HCV in the 
pathogenesis of interstitial pneumonitis is not understood, 
but chronic immune activation and inflammation that is 
induced  by  HCV  infection  may  be  involved.  Because  HCV 
induces chronic inflammation and fibrosis in the liver, HCV 
is believed to have similar functions in the lung and might 
mediate the pathogenesis of pulmonary fibrosis. The other 
possible mechanism is that antigens and antibodies from 
the bowel or other organs enter portal circulation and are 
not separated sufficiently in patients with severe liver dys-
function. Immune complexes that are formed by these an-
tigens and antibodies enter systemic circulation and accu-
mulate in the glomeruli or lung (29). Arase et al. examined 
the lung and kidney by immunofluorescence microscopy; 
they did not detect immunoglobulin in formalin-fixed lung 
tissue but detected it in the glomeruli of patients with me-73 Aliannejad R  et al. Hepatitis C and pulmonary fibrosis
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sangial  and  membranoproliferative  glomerulonephritis 
(29).  These  results  indicate  that  serum  immunoglobulin 
has a minor role in IPF. However, there might have been low 
sensitivity due to the use of formalin-fixed tissue. The func-
tion  of  inflammation  in  the  development  of  IPF  remains 
unresolved. Histologically and radiologically (ground glass 
densities of IPF by CT), there is modest evidence to support 
the involvement of inflammation in IPF patients. IPF may 
occur in susceptible individuals with abnormal lung repair 
mechanisms. Therefore, several environmental insults, such 
as viral infections, could effect and perpetuate IPF. However, 
inflammation can lead to fibrosis in other clinical entities 
(30). Conversely, some conditions, such as MC and sicca syn-
drome, are observed in HCV infection and can involve the 
lung with or without clinical symptoms (9, 10, 12). Some MC 
patients may present with dyspnea of exertion, dry cough, 
interstitial lung fibrosis, pleural effusions, or hemoptysis, 
which can be a consequence of alveolar hemorrhage. Koike 
et al. reported that transgenic mice that carry the HCV en-
velope gene develop exocrinopathy that resembles Sjogren 
syndrome (31).The incidence of IPF has not been examined in 
Iran. A recent systematic review has indicated that the preva-
lence of HCV infection in Iran is 0.16%, which is low compared 
with other countries (32). Therefore, this evidence should 
prompt studies on the correlation or a causal relationship 
between HCV and IPF. More extensive cohort studies should 
be conducted to determine whether there is a causal rela-
tionship between HCV infection and pulmonary fibrosis. 
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